EGFR and lung carcinoma: At baseline, both control and inhibitor‐treated A431 lung cancer cells released DNA‐positive EVs of different sizes; however, the total number of DNA‐carrying EVs increased following exposure to the EGFR inhibitors, and also led to the emergence of another population of DNA‐positive nonvesicular particles.